



# Clinical Therapeutics

The International  
Peer-Reviewed Journal  
of Drug Therapy

Volume 39, Number 3, March 2017

---

## Editor-In-Chief's Note

---

- 451 Placebos, Active Placebos, and Clinical Trials  
*Richard I. Shader*

## CURRENT INSIGHTS IN THE PLACEBO AND NOCEBO PHENOMENA

### Editorial

---

- 456 Current Insights in the Placebo and Nocebo Phenomena  
*Seetal Dodd*

### Reviews

---

- 458 Unsolved, Forgotten, and Ignored Features of the Placebo Response in Medicine  
*Paul Enck, Sibylle Klosterhalfen, and Katja Weimer*
- 469 A Review of the Theoretical and Biological Understanding of the Nocebo and Placebo Phenomena  
*Seetal Dodd, Olivia M. Dean, João Vian, and Michael Berk*
- 477 The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes  
*Victor Chavarria, João Vian, Círia Pereira, João Data-Franco, Brisa S. Fernandes, Michael Berk, and Seetal Dodd*

### Original Research

---

- 487 Different Disclosed Probabilities to Receive an Antiemetic Equally Decrease Subjective Symptoms in an Experimental Placebo Study: To Be or Not to Be Sure  
*Katja Weimer, Björn Horing, Eric R. Muth, Jenna L. Scisco, Sibylle Klosterhalfen, and Paul Enck*
- 502 Cognitive Schemas in Placebo and Nocebo Responding: Role of Autobiographical Memories and Expectations  
*Danielle J.P. Bartels, Antoinette I.M. van Laarhoven, Naomi Heijmans, Dirk Hermans, Elise Debeer, Peter C.M. van de Kerkhof, Andrea W.M. Evers*

## FEATURED CONTENT

### Original Research

---

- 514 *Express Track:* Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants  
*Anita H. Clayton, Johna Lucas, Leonard R. DeRogatis, and Robert Jordan*
- 527 *Express Track:* Health Care Utilization and Direct Costs in Mild, Moderate, and Severe Adult Asthma: A Descriptive Study Using the 2014 South Korean Health Insurance Database  
*Yoo Ju Lee, Sun-Hong Kwon, Sung-Hyun Hong, Jin Hyun Nam, Hyun Jin Song, Jong Seop Lee, Eui-Kyung Lee, and Ju-Young Shin*
- 537 *Express Track:* Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis  
*Erkki Soini, Jaana Joutseno, and Marja-Liisa Sumelahti*
- 558 Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease  
*Koichi Yabiku, Akiko Mutoh, Kazufumi Miyagi, and Nobuyuki Takasu*

Continued on next page

- 567** Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective  
*Stefano Capri, Camillo Porta, and Thomas E. Delea*
- 581** A Novel  $\omega$ -3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies™ (ALT®) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza®  
*Miguel A. Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed Daak, Kevin C. Maki, Colleen Johns, Adrian L. Rabinowicz, and Frederick D. Sancilio*
- 592** Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care Setting  
*Lisa C. Brown, Raymond A. Lorenz, James Li, and Bryan M. Dechairo*
- 603** Cost of Bleeding-related Episodes in Adult Patients With Primary Immune Thrombocytopenia: A Population-based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States  
*Junji Lin, Xinke Zhang, Xiaoyan Li, David Chandler, Ivy Altomare, Jeffrey S. Wasser, and Karynsa Cetin*
- 610** Retrospective Analysis of Different Treatment Schemes After Gefitinib Resistance in Advanced Non-small Cell Lung Cancer  
*Huijuan Wang, Mina Zhang, Peng Li, Guowei Zhang, Xiangtao Yan, and Zhiyong Ma*
- 620** Effects of Pitavastatin on Lipid-rich Carotid Plaques Studied Using High-resolution Magnetic Resonance Imaging  
*Tao Feng, Xiaoxing Huang, Qundi Liang, Yun Liang, Yong Yuan, Li Feng, Wenjun Wu, Xuehong Xiao, and Ying Han*
- Review**
- 
- 632** Interleukin-10: A Compelling Therapeutic Target in Patients With Irritable Bowel Syndrome  
*Sunil Kumar, Ratnakar Shukla, Prabhat Ranjan, and Awanish Kumar*
- Brief Report**
- 
- 646** Choosing Wisely: The Top-5 Recommendations from the Italian Panel of the National Guidelines for the Management of Acute Pharyngitis in Children  
*Elena Chiappini, Barbara Bortone, Giuseppe Di Mauro, Susanna Esposito, Luisa Galli, Massimo Landi, Andrea Novelli, Paola Marchisio, Gian Luigi Marseglia, Nicola Principi, Maurizio de Martino and for the Italian Panel on the Management of Pharyngitis in Children*
- Commentaries**
- 
- 652** Bioequivalence Demonstration for  $\Omega$ -3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance  
*Kevin C. Maki, Colleen Johns, William S. Harris, Mark Puder, Steven D. Freedman, Thorsteinn Thorsteinsson, Ahmed Daak, Adrian L. Rabinowicz, and Frederick D. Sancilio*
- 659** Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?  
*Leonardo Roever, Giuseppe Biondi-Zoccai, and Sunil V. Rao*
- Errata**
- 
- 662** Corrigendum to ‘Demographic and Clinical Characteristics of Type 2 Diabetes Mellitus Patients Initiating Dipeptidyl Peptidase-4 Inhibitors - A Retrospective Study of UK General Practice’  
*Abigail Tebboth, Sally Lee, Anna Scowcroft, Paula Bingham-Gardiner, William Spencer, John Bolodeoku, and Syed Wasi Hassan*
- 663** Erratum to ‘Pitavastatin vs Pravastatin in Reduction of Remnant Lipoprotein Cholesterol in Patients with Dyslipidemias’  
*Leonardo Roever*